Pfizer is expanding the company’s presence in infectious diseases with the acquisition of San Diego-based Amplyx Pharmaceuticals and the lead antifungal compound Fosmanogepix (APX001).

The Novartis Institutes for BioMedical Research is ending its early-stage anti-infectives research programs located in Emeryville, Calif. As a result, the company expects to lay off about 140 employees.

Pfizer Inc. announced that the company will organize into three businesses: Innovative Medicines, Established Medicines, and Consumer Healthcare.

Vyera Pharmaceuticals – formerly known as Turing Pharmaceuticals – does not have to pay Impax Laboratories $43 million in a dispute stemming from Turing founder Martin Shkreli’s decision to boost by 5,000 percent the price of a drug Turing bought from Impax, a U.S. judge ruled.

After hitting its milestone mark, Warp Drive Bio is turning over its novel antibiotic compounds to Sanofi, which will take over all preclinical and clinical development operations.